Alembic Pharmaceuticals completes USFDA RRA for its bioequivalence facility

Alembic Pharmaceuticals completes USFDA RRA for its bioequivalence facility

By: IPP Bureau

Last updated : August 29, 2022 10:10 pm



The RRA was conducted from 22nd August, 2022 to 26th August, 2022.


Alembic Pharmaceuticals Limited has successfully completed the US Food and Drug Administration (USFDA) Remote Regulatory Assessment (RRA) for its Bioequivalence Facility, Bio-analytical division, located at Vadodara, without any observations.

The RRA was conducted from 22nd August, 2022 to 26th August, 2022.

Alembic Pharmaceuticals USFDA

First Published : August 29, 2022 12:00 am